Cardiovascular (CV) events are associated with an increased risk of kidney disease progression.1 However, little is known about the trajectory of kidney function change after a CV event, particularly in people treated with contemporary kidney-protective medications such as sodium-glucose cotransporter 2 (SGLT2) inhibitors. We performed a post hoc analysis using data from the eValuation of ERTtugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS CV; protocol MK-8835-004; ClinicalTrials.gov: NCT01986881) to assess if the association between interval CV events (ICVEs) and kidney outcomes differed between the ertugliflozin and placebo groups.